ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levels; Conf ...

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...

First Tracks Biotherapeutics offers a differentiated CD122 antagonist, ANB033, showing promising Phase 1b data in celiac ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted ...

XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumorsAnticipate ...

Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 ...

An entirely computational study reports that three designed 9-anilinoacridine derivatives show favourable predicted binding to estrogen receptor-alpha, with compound II(f) prioritized on the basis of ...

What Research Shows About Cancer Risk and Prevention / Breast Cancer, cancer, Cancer Prevention, Cancer research, cancer risk ...

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no ...

A review identifies post-endocytic routing as the decisive step in targeted lysosomal degradation and proposes a five-tier ...

Results presented at ESMO show a promising therapeutic index for [212Pb]VMT-α-NETDurable disease control in all three cohorts and 72% PFS at 18 ...

Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today ...